The Claim
TSH-secreting pituitary adenomas exhibit biological heterogeneity in their response to thyroid hormone feedback, with some tumors remaining stable under long-term supraphysiologic levothyroxine therapy, challenging the notion of uniform resistance.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Some TSH-secreting pituitary tumors do not shrink or change in size when treated with high doses of levothyroxine, indicating that these tumors vary in how they respond to thyroid hormone suppression.
See the scientific wording
TSH-secreting pituitary adenomas may exhibit biological heterogeneity in their response to thyroid hormone feedback, as evidenced by a tumor that remained stable for two decades under supraphysiologic levothyroxine therapy, contrary to the traditional view that these tumors are uniformly resistant.
High levels of thyroid hormone enter the pituitary gland and bind to specific receptors on tumor cells, which turns down the production of the hormone that stimulates the thyroid. This reduces the signal that makes the tumor grow, so the tumor stays small even when thyroid hormone levels are very high.
What the research says
1 studyA woman was given high doses of thyroid hormone for 20 years because doctors thought she had an underactive thyroid, but she actually had a rare brain tumor that makes too much thyroid-stimulating hormone. Surprisingly, the tumor didn’t grow during all those years of extra hormone — suggesting it might still listen to the hormone signals, unlike what doctors used to think.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.